Circulating miRNAs as new blood-based biomarkers for solid
cancers

J 2013

Circulating miRNAs as new blood-based biomarkers for solid cancers

RÉDOVÁ, Martina, Jiří ŠÁNA and Ondřej SLABÝ

Basic information

Original name

Circulating miRNAs as new blood-based biomarkers for solid cancers

Authors

RÉDOVÁ, Martina (203 Czech Republic, belonging to the institution), Jiří ŠÁNA (203 Czech Republic, belonging to the institution) and Ondřej SLABÝ (203 Czech Republic, guarantor, belonging to the institution)

Edition

Future Oncology, London, Future Medicine Ltd. 2013, 1479-6694

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.611

RIV identification code

RIV/00216224:14740/13:00065587

Organization unit

Central European Institute of Technology

DOI

http://dx.doi.org/10.2217/FON.12.192

UT WoS

000315966900013

Keywords in English

biomarkers; breast cancer; colorectal cancer; lung cancer; miRNA; plasma; prostate cancer; serum

Abstract

V originále

miRNAs are short noncoding RNAs that post-transcriptionally regulate gene expression. miRNAs' ability to inhibit translation of oncogenes and tumor suppressor genes implies they have an involvement in carcinogenesis. Specific miRNA expression signatures have been identified in a variety of human cancers. More recently, occurrence of miRNAs in the blood serum and plasma of humans has been repeatedly observed. miRNA levels in serum and plasma are more stable, reproducible and consistent among individuals of the same species in comparison with other circulating nucleic acids. Circulating miRNAs have been successfully evaluated in a wide range of solid cancers as promising novel noninvasive biomarkers of early disease onset or relapse. Here we describe the origin of circulating miRNAs, principles of their immense stability and proposed functions, and comprehensively summarize studies focusing on their significance in the most frequently studied cancer types in this regard, including breast, colorectal, lung and prostate cancer.

Links

ED1.1.00/02.0068, research and development project

Name: CEITEC - central european institute of technology

NT13549, research and development project

Name: Vytvoření diagnostické sady cirkulujících mikroRNA pro neinvazivní časnou diagnostiku a sledování pacientů s kolorektálním karcinomem

Citovat

RÉDOVÁ, Martina, Jiří ŠÁNA and Ondřej SLABÝ. Circulating miRNAs as new blood-based biomarkers for solid cancers. Future Oncology. London: Future Medicine Ltd., 2013, vol. 9, No 3, p. 387-402, 6 pp. ISSN 1479-6694. Available from: https://dx.doi.org/10.2217/FON.12.192.

@article{1103755,
   author = {Rédová, Martina and Šána, Jiří and Slabý, Ondřej},
   article_location = {London},
   article_number = {3},
   doi = {http://dx.doi.org/10.2217/FON.12.192},
   keywords = {biomarkers; breast cancer; colorectal cancer; lung cancer; miRNA; plasma; prostate cancer; serum},
   language = {eng},
   issn = {1479-6694},
   journal = {Future Oncology},
   title = {Circulating miRNAs as new blood-based biomarkers for solid cancers},
   volume = {9},
   year = {2013}
}

TY  - JOUR
ID  - 1103755
AU  - Rédová, Martina - Šána, Jiří - Slabý, Ondřej
PY  - 2013
TI  - Circulating miRNAs as new blood-based biomarkers for solid cancers
JF  - Future Oncology
VL  - 9
IS  - 3
SP  - 387-402
EP  - 387-402
PB  - Future Medicine Ltd.
SN  - 14796694
KW  - biomarkers
KW  - breast cancer
KW  - colorectal cancer
KW  - lung cancer
KW  - miRNA
KW  - plasma
KW  - prostate cancer
KW  - serum
N2  - miRNAs are short noncoding RNAs that post-transcriptionally regulate gene expression. miRNAs' ability to inhibit translation of oncogenes and tumor suppressor genes implies they have an involvement in carcinogenesis. Specific miRNA expression signatures have been identified in a variety of human cancers. More recently, occurrence of miRNAs in the blood serum and plasma of humans has been repeatedly observed. miRNA levels in serum and plasma are more stable, reproducible and consistent among individuals of the same species in comparison with other circulating nucleic acids. Circulating miRNAs have been successfully evaluated in a wide range of solid cancers as promising novel noninvasive biomarkers of early disease onset or relapse. Here we describe the origin of circulating miRNAs, principles of their immense stability and proposed functions, and comprehensively summarize studies focusing on their significance in the most frequently studied cancer types in this regard, including breast, colorectal, lung and prostate cancer.
ER  -

RÉDOVÁ, Martina, Jiří ŠÁNA and Ondřej SLABÝ. Circulating miRNAs as new blood-based biomarkers for solid cancers. \textit{Future Oncology}. London: Future Medicine Ltd., 2013, vol.~9, No~3, p.~387-402, 6 pp. ISSN~1479-6694. Available from: https://dx.doi.org/10.2217/FON.12.192.

Detailed Information on Publication Record